GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (ASX:RAC) » Definitions » Net-Net Working Capital

Race Oncology (ASX:RAC) Net-Net Working Capital : A$0.10 (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Race Oncology Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Race Oncology's Net-Net Working Capital for the quarter that ended in Dec. 2024 was A$0.10.

The industry rank for Race Oncology's Net-Net Working Capital or its related term are showing as below:

ASX:RAC's Price-to-Net-Net-Working-Capital is ranked worse than
82.42% of 859 companies
in the Biotechnology industry
Industry Median: 3.98 vs ASX:RAC: 14.20

Race Oncology Net-Net Working Capital Historical Data

The historical data trend for Race Oncology's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Race Oncology Net-Net Working Capital Chart

Race Oncology Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only 0.01 0.06 0.20 0.12 0.09

Race Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.12 0.10 0.09 0.10

Competitive Comparison of Race Oncology's Net-Net Working Capital

For the Biotechnology subindustry, Race Oncology's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Race Oncology's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Race Oncology's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Race Oncology's Price-to-Net-Net-Working-Capital falls into.


;
;

Race Oncology Net-Net Working Capital Calculation

Race Oncology's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Jun. 2024 is calculated as

Net-Net Working Capital(A: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(17.189+0.75 * 0+0.5 * 0-1.916
-0-0)/170.304
=0.09

Race Oncology's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2024 is calculated as

Net-Net Working Capital(Q: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(18.782+0.75 * 0.04+0.5 * 0-0.957
-0-0)/173.713
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Race Oncology  (ASX:RAC) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Race Oncology Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Race Oncology's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Race Oncology Business Description

Traded in Other Exchanges
N/A
Address
1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors.